![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB |
![[thumbnail of Supplementary Materials]](https://mdc-test.eprints-hosting.org/style/images/fileicons/other.png) |
Other (Supplementary Materials)
2MB |
| Item Type: | Article |
|---|---|
| Title: | Frequency and predictors of relapses following SARS-CoV-2 vaccination in patients with multiple sclerosis: interim results from a longitudinal observational study |
| Creators Name: | Frahm, N., Fneish, F., Ellenberger, D., Haas, J., Löbermann, M., Peters, M., Pöhlau, D., Röper, A.L., Schilling, S., Stahmann, A., Temmes, H., Paul, F. and Zettl, U.K. |
| Abstract: | Despite protection from severe COVID-19 courses through vaccinations, some people with multiple sclerosis (PwMS) are vaccination-hesitant due to fear of post-vaccination side effects/increased disease activity. The aim was to reveal the frequency and predictors of post-SARS-CoV-2-vaccination relapses in PwMS. This prospective, observational study was conducted as a longitudinal Germany-wide online survey (baseline survey and two follow-ups). Inclusion criteria were age ≥18 years, MS diagnosis, and ≥1 SARS-CoV-2 vaccination. Patient-reported data included socio-demographics, MS-related data, and post-vaccination phenomena. Annualized relapse rates (ARRs) of the study cohort and reference cohorts from the German MS Registry were compared pre- and post-vaccination. Post-vaccination relapses were reported by 9.3% PwMS (247/2661). The study cohort’s post-vaccination ARR was 0.189 (95% CI: 0.167–0.213). The ARR of a matched unvaccinated reference group from 2020 was 0.147 (0.129–0.167). Another reference cohort of vaccinated PwMS showed no indication of increased post-vaccination relapse activity (0.116; 0.088–0.151) compared to pre-vaccination (0.109; 0.084–0.138). Predictors of post-vaccination relapses (study cohort) were missing immunotherapy (OR = 2.09; 1.55–2.79; p < 0.001) and shorter time from the last pre-vaccination relapse to the first vaccination (OR = 0.87; 0.83–0.91; p < 0.001). Data on disease activity of the study cohort in the temporal context are expected for the third follow-up. |
| Keywords: | SARS-CoV-2, COVID-19, Vaccination, Multiple Sclerosis, Relapse |
| Source: | Journal of Clinical Medicine |
| ISSN: | 2077-0383 |
| Publisher: | MDPI |
| Volume: | 12 |
| Number: | 11 |
| Page Range: | 3640 |
| Date: | 24 May 2023 |
| Official Publication: | https://doi.org/10.3390/jcm12113640 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
